


## CLAIMS

1. A compound of formula I:



**I**

or a pharmaceutically acceptable salt thereof,

wherein:

$R^1$  is hydrogen or halogen;


$R^2$  is substituted or unsubstituted cycloalkyl;

each occurrence of  $R^3$  is independently halogen, alkyl,  $-(CH_2)_mOR^4$ ,  $-(CH_2)_mSR^4$ ,  $-(CH_2)_mN(R^4)_2$ ,  $-(CH_2)_mNR^4C(O)R^4$ ,  $-(CH_2)_mNR^4C(O)N(R^4)_2$ ,  $-(CH_2)_mNR^4CO_2R^4$ ,  $-(CH_2)_mCO_2R^4$ ,  $-(CH_2)_mC(O)R^4$ ,  $-(CH_2)_mC(O)N(R^4)_2$ ,  $-(CH_2)_mOC(O)N(R^4)_2$ ,  $-(CH_2)_mS(O)_2R^4$ ,  $-(CH_2)_mSO_2N(R^4)_2$ ,  $-(CH_2)_mS(O)R^4$ ,  $-(CH_2)_mNR^4SO_2N(R^4)_2$ ,  $-(CH_2)_mNR^4SO_2R^4$ ,  $-(CH_2)_mC(=S)N(R^4)_2$ , wherein m is 0, 1 or 2 and  $R^4$  is hydrogen or alkyl;

r is 0, 1 or 2; and

n is 0, 1 or 2.

2. The compound of claim 1, wherein  $R^1$  is hydrogen or fluorine;  $R^2$  is substituted or unsubstituted cycloalkyl; r is 0 or 1;  $R^3$  is alkyl, or  $-(CH_2)_mOR^4$ , wherein m is 0, 1 or 2 and  $R^4$  is hydrogen or alkyl; and n is 0, 1 or 2.
3. The compound of claim 1, wherein  $R^2$  is substituted or unsubstituted norbornyl and compounds have the formula II:



## II

wherein  $R^1$  is hydrogen or halogen;

each occurrence of  $R^3$  is independently halogen, alkyl,  $-(CH_2)_mOR^4$ ,  $-(CH_2)_mSR^4$ ,  $-(CH_2)_mN(R^4)_2$ ,  $-(CH_2)_mNR^4C(O)R^4$ ,  $-(CH_2)_mNR^4C(O)N(R^4)_2$ ,  $-(CH_2)_mNR^4CO_2R^4$ ,  $-(CH_2)_mCO_2R^4$ ,  $-(CH_2)_mC(O)R^4$ ,  $-(CH_2)_mC(O)N(R^4)_2$ ,  $-(CH_2)_mOC(O)N(R^4)_2$ ,  $-(CH_2)_mS(O)_2R^4$ ,  $-(CH_2)_mSO_2N(R^4)_2$ ,  $-(CH_2)_mS(O)R^4$ ,  $-(CH_2)_mNR^4SO_2N(R^4)_2$ ,  $-(CH_2)_mNR^4SO_2R^4$ ,  $-(CH_2)_mC(=S)N(R^4)_2$ , wherein  $m$  is 0, 1 or 2 and  $R^4$  is hydrogen or alkyl;


$n$  is 0, 1 or 2;

$r$  is 0, 1 or 2;

each occurrence of  $R^5$  is independently halogen, alkyl,  $-(CH_2)_qOR^6$ ,  $-(CH_2)_qSR^6$ ,  $-(CH_2)_qN(R^6)_2$ ,  $-(CH_2)_qNR^6C(O)R^6$ ,  $-(CH_2)_qNR^6C(O)N(R^6)_2$ ,  $-(CH_2)_qNR^6CO_2R^6$ ,  $-(CH_2)_qCO_2R^6$ ,  $-(CH_2)_qC(O)R^6$ ,  $-(CH_2)_qC(O)N(R^6)_2$ ,  $-(CH_2)_qOC(O)N(R^6)_2$ ,  $-(CH_2)_qS(O)_2R^6$ ,  $-(CH_2)_qSO_2N(R^6)_2$ ,  $-(CH_2)_qS(O)R^6$ ,  $-(CH_2)_qNR^6SO_2N(R^6)_2$ ,  $-(CH_2)_qNR^6SO_2R^6$ ,  $-(CH_2)_qC(=S)N(R^6)_2$ , wherein  $q$  is 0, 1 or 2, and each occurrence of  $R^6$  is independently hydrogen or alkyl; and

$p$  is 0, 1 or 2.

4. The compound of claim 1, wherein  $R^2$  is substituted or unsubstituted cyclohexyl and compounds have the formula **III**:



### III

wherein  $R^1$  is hydrogen or halogen;

each occurrence of  $R^3$  is independently halogen, alkyl,  $-(CH_2)_mOR^4$ ,  $-(CH_2)_mSR^4$ ,  $-(CH_2)_mN(R^4)_2$ ,  $-(CH_2)_mNR^4C(O)R^4$ ,  $-(CH_2)_mNR^4C(O)N(R^4)_2$ ,  $-(CH_2)_mNR^4CO_2R^4$ ,  $-(CH_2)_mCO_2R^4$ ,  $-(CH_2)_mC(O)R^4$ ,  $-(CH_2)_mC(O)N(R^4)_2$ ,  $-(CH_2)_mOC(O)N(R^4)_2$ ,  $-(CH_2)_mS(O)_2R^4$ ,  $-(CH_2)_mSO_2N(R^4)_2$ ,  $-(CH_2)_mS(O)R^4$ ,  $-(CH_2)_mNR^4SO_2N(R^4)_2$ ,  $-(CH_2)_mNR^4SO_2R^4$ ,  $-(CH_2)_mC(=S)N(R^4)_2$ , wherein  $m$  is 0, 1 or 2 and  $R^4$  is hydrogen or alkyl;

$n$  is 0, 1 or 2;

$r$  is 0, 1 or 2;

each occurrence of  $R^5$  is independently hydrogen, halogen, alkyl,  $-(CH_2)_qOR^6$ ,  $-(CH_2)_qSR^6$ ,  $-(CH_2)_qN(R^6)_2$ ,  $-(CH_2)_qNR^6C(O)R^6$ ,  $-(CH_2)_qNR^6C(O)N(R^6)_2$ ,  $-(CH_2)_qNR^6CO_2R^6$ ,  $-(CH_2)_qCO_2R^6$ ,  $-(CH_2)_qC(O)R^6$ ,  $-(CH_2)_qC(O)N(R^6)_2$ ,  $-(CH_2)_qOC(O)N(R^6)_2$ ,  $-(CH_2)_qS(O)_2R^6$ ,  $-(CH_2)_qSO_2N(R^6)_2$ ,  $-(CH_2)_qS(O)R^6$ ,  $-(CH_2)_qNR^6SO_2N(R^6)_2$ ,  $-(CH_2)_qNR^6SO_2R^6$ ,  $-(CH_2)_qC(=S)N(R^6)_2$ , wherein  $q$  is 0, 1 or 2 and each occurrence of  $R^6$  is independently hydrogen or alkyl; and

$p$  is 0, 1 or 2.


5. The compound of claim 1, wherein  $R^1$  is F.

6. The compound of claim 1, wherein  $R^1$  is H.


7. The compound of claim 1, wherein  $r$  is 0 or  $r$  is 1 and  $R^3$  is alkyl, OH,  $CH_2OH$ , or alkoxy.

8. The compound of claim 1, wherein  $n$  is 0.


9. The compound of claim 1, wherein n is 1.
10. The compound of claim 1, wherein n is 2.
11. The compound of claim 3, wherein p is 0.
12. The compound of claim 4, wherein p is 0.
13. The compound of claim 4, wherein p is 1.
14. The compound of claim 4, wherein p is 2.
15. The compound of claim 3 or 4, wherein p is 0 or 1 and R<sup>5</sup> is OH, or alkyl.
16. The compound of claim 3, wherein R<sup>1</sup> is F or H; p is 0; n is 0 or 1; r is 0 or 1; and R<sup>3</sup> is OH, CH<sub>2</sub>OH, alkyl or alkoxy.
17. The compound of claim 4, wherein R<sup>1</sup> is F or H; p is 0, 1 or 2; each occurrence of R<sup>5</sup> is independently alkyl, OH, CH<sub>2</sub>OH or alkoxy; n is 0 or 1; r is 0 or 1; and R<sup>3</sup> is OH, CH<sub>2</sub>OH, alkyl or alkoxy.
18. The compound of claim 1, wherein the compound has one of the following structures:




**I-1**




**I-2**




**I-3**




**I-4**




**I-5**




**I-6**




**I-7**




**I-8**




**I-9**




**I-10**




**I-11**




**I-12**




**I-13**




**I-14**




**I-15**




**I-16**




**I-17**



**I-18**



**I-19**



**I-20**

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
20. The composition according to claim 19, further comprising an additional therapeutic agent selected from a treatment for stroke, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, or an agent for treating an immunodeficiency disorder.
21. A method of treating a neurodegenerative, neurological, ischemic or inflammatory disorder comprising administering a therapeutically effective amount of a compound of claim 1.
22. The method according to claim 21, wherein the ischemic disorder is stroke.
23. The method according to claim 22, comprising the further step of :  
administering to said patient an additional therapeutic agent selected from a treatment for stroke, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor,

an agent for treating cardiovascular disease, or an agent for treating an immunodeficiency disorder wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.